KemPharm Company Profile (NASDAQ:KMPH)

About KemPharm (NASDAQ:KMPH)

KemPharm logoKemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KMPH
  • CUSIP: N/A
  • Web:
  • Market Cap: $49.07 million
  • Outstanding Shares: 14,648,000
Average Prices:
  • 50 Day Moving Avg: $4.02
  • 200 Day Moving Avg: $3.91
  • 52 Week Range: $2.90 - $5.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.74
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($2.32) per share
  • Price / Book: -1.47
  • EBIDTA: ($34,650,000.00)
  • Return on Assets: -28.72%
  • Debt-to-Equity Ratio: -2.70%
  • Current Ratio: 13.13%
  • Quick Ratio: 13.13%
  • Average Volume: 29,378 shs.
  • Beta: -1.23
  • Short Ratio: 30.25

Frequently Asked Questions for KemPharm (NASDAQ:KMPH)

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How were KemPharm's earnings last quarter?

KemPharm, Inc. (NASDAQ:KMPH) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.21. View KemPharm's Earnings History.

Where is KemPharm's stock going? Where will KemPharm's stock price be in 2017?

3 analysts have issued twelve-month price targets for KemPharm's stock. Their forecasts range from $7.00 to $13.00. On average, they anticipate KemPharm's stock price to reach $9.33 in the next year. View Analyst Ratings for KemPharm.

Who are some of KemPharm's key competitors?

Who are KemPharm's key executives?

KemPharm's management team includes the folowing people:

  • Travis C. Mickle Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Timothy J. Sangiovanni, Principal Accounting Officer, Vice President, Corporate Controller
  • Gordon K. Johnson, Chief Business Officer

When did KemPharm IPO?

(KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Who owns KemPharm stock?

KemPharm's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Arete Wealth Advisors LLC (5.81%), Creative Planning (3.10%), Vanguard Group Inc. (2.05%), C WorldWide Group Holding A S (1.24%), Victory Capital Management Inc. (0.90%) and Parkwood LLC (0.86%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, R Laduane Clifton and Travis C Mickle. View Institutional Ownership Trends for KemPharm.

Who sold KemPharm stock? Who is selling KemPharm stock?

KemPharm's stock was sold by a variety of institutional investors in the last quarter, including Menta Capital LLC. View Insider Buying and Selling for KemPharm.

Who bought KemPharm stock? Who is buying KemPharm stock?

KemPharm's stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Morgan Stanley, C WorldWide Group Holding A S, Creative Planning, Bank of New York Mellon Corp, Arete Wealth Advisors LLC, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, R Laduane Clifton and Travis C Mickle. View Insider Buying and Selling for KemPharm.

How do I buy KemPharm stock?

Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KemPharm's stock price today?

One share of KemPharm stock can currently be purchased for approximately $3.40.

MarketBeat Community Rating for KemPharm (NASDAQ KMPH)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for KemPharm (NASDAQ:KMPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.33 (174.51% upside)

Analysts' Ratings History for KemPharm (NASDAQ:KMPH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Royal Bank Of CanadaReiterated RatingBuy$8.00MediumView Rating Details
5/10/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$13.00LowView Rating Details
3/12/2017Canaccord GenuitySet Price TargetBuy$7.00HighView Rating Details
8/15/2015Cowen and CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 6/27/2015 forward)


Earnings History for KemPharm (NASDAQ:KMPH)
Earnings by Quarter for KemPharm (NASDAQ:KMPH)
Earnings History by Quarter for KemPharm (NASDAQ KMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.63)($0.84)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.70)($0.68)ViewListenView Earnings Details
11/9/2016Q3 2016($0.70)($0.92)ViewListenView Earnings Details
8/10/2016Q2($0.94)($0.58)ViewListenView Earnings Details
5/12/2016Q1($0.56)($0.20)ViewListenView Earnings Details
3/10/2016Q4($0.50)($0.64)ViewListenView Earnings Details
11/12/2015Q315($0.48)($0.68)ViewListenView Earnings Details
8/13/2015Q215($0.47)($0.59)ViewListenView Earnings Details
5/27/2015Q1($0.49)($2.50)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for KemPharm (NASDAQ:KMPH)
2017 EPS Consensus Estimate: ($2.78)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.69)($0.69)($0.69)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.66)($0.66)($0.66)
Q4 20171($0.80)($0.80)($0.80)
(Data provided by Zacks Investment Research)


Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for KemPharm (NASDAQ:KMPH)
Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 42.11%
Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)
Institutional Ownership by Quarter for KemPharm (NASDAQ:KMPH)
Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/20/2017Travis C MickleCEOBuy8,000$3.45$27,600.00View SEC Filing  
6/19/2017R. Laduane CliftonCFOBuy275$3.30$907.50View SEC Filing  
5/25/2017Daniel L CohenEVPBuy2,500$4.11$10,275.00View SEC Filing  
3/31/2017Daniel L CohenEVPBuy2,500$4.48$11,200.00View SEC Filing  
3/24/2017R. Laduane CliftonCFOBuy1,000$4.24$4,240.00View SEC Filing  
3/22/2017Travis C MickleCEOBuy2,000$4.10$8,200.00View SEC Filing  
3/20/2017David S TierneyDirectorBuy1,000$4.20$4,200.00View SEC Filing  
11/30/2016Daniel L CohenEVPBuy5,000$3.50$17,500.00View SEC Filing  
9/6/2016Daniel L CohenEVPBuy10,000$4.75$47,500.00View SEC Filing  
8/17/2016Travis C MickleCEOBuy5,000$4.95$24,750.00View SEC Filing  
3/29/2016Travis C MickleCEOBuy2,450$14.57$35,696.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for KemPharm (NASDAQ:KMPH)
Latest Headlines for KemPharm (NASDAQ:KMPH)
DateHeadline logoKemPharm (KMPH) Granted First Patent for KP746 - June 26 at 8:05 PM logoKemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone - June 26 at 8:05 PM logoKemPharm, Inc. (KMPH) CEO Buys $27,600.00 in Stock - June 21 at 1:25 PM logoKemPharm, Inc. (KMPH) Expected to Post Earnings of -$0.63 Per Share - June 15 at 6:28 PM logoKemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids - June 9 at 9:20 AM logoKemPharm Announces Addition to Leadership Team - June 1 at 7:51 AM logoKemPharm Inc (KMPH) Lowered to "Sell" at Zacks Investment Research - May 28 at 5:56 PM logoDaniel L. Cohen Purchases 2,500 Shares of KemPharm Inc (KMPH) Stock - May 26 at 8:29 PM logoQ2 2017 EPS Estimates for KemPharm Inc Reduced by Oppenheimer Holdings (KMPH) - May 15 at 7:46 AM logoFY2021 EPS Estimates for KemPharm Inc (KMPH) Cut by Analyst - May 12 at 6:56 PM logoKemPharm Inc (KMPH) Announces Quarterly Earnings Results - May 11 at 7:36 PM logoKemPharm Inc (KMPH) Given a $13.00 Price Target by Oppenheimer Holdings Inc. Analysts - May 11 at 2:56 PM logoKemPharma reports 1Q loss - May 10 at 6:06 PM logoKemPharm, Inc. Reports First Quarter 2017 Results - May 10 at 6:06 PM logoInvestor Network: KemPharm, Inc. to Host Earnings Call - May 10 at 1:04 PM logoKemPharm Inc (KMPH) Rating Increased to Buy at Zacks Investment Research - May 5 at 12:46 AM logoKemPharm (KMPH) Receiving Somewhat Favorable Press Coverage, Report Finds - May 4 at 2:18 PM logoKemPharm Inc (KMPH) Downgraded by Zacks Investment Research - May 4 at 1:17 AM logoZacks Investment Research Downgrades KemPharm Inc (KMPH) to Hold - May 4 at 1:16 AM logoKemPharm (KMPH) Getting Somewhat Negative Press Coverage, Study Finds - May 1 at 3:42 PM logoKemPharm, Inc. to Report First Quarter 2017 Results - May 1 at 1:00 PM logoZacks: Analysts Expect KemPharm Inc (KMPH) to Announce -$0.61 Earnings Per Share - April 27 at 11:20 PM logoKemPharm (KMPH) Receives News Sentiment Rating of 0.31 - April 20 at 11:49 PM logoKemPharm (KMPH) Earns News Impact Score of 0.31 - April 17 at 9:10 AM logoKemPharm Inc (KMPH) Given a $8.00 Price Target at Royal Bank of Canada - April 13 at 6:14 PM logoKemPharm (KMPH) Earning Favorable News Coverage, Study Finds - April 13 at 3:18 PM logoKemPharm Inc (KMPH) Expected to Post Quarterly Sales of $0.00 - April 8 at 9:07 AM logo-$0.61 EPS Expected for KemPharm Inc (KMPH) This Quarter - April 6 at 6:18 PM logo Brokerages Set $27.33 Target Price for KemPharm Inc (KMPH) - April 4 at 12:43 AM logoZacks Investment Research Upgrades KemPharm Inc (KMPH) to "Hold" - April 2 at 9:55 AM logoKEMPHARM, INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits - March 28 at 5:46 PM logoKemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum - March 27 at 10:43 AM logoKemPharm Inc (KMPH) Stock Rating Reaffirmed by Oppenheimer Holdings Inc. - March 24 at 11:04 PM logoKemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting - March 16 at 6:58 PM logo7:32 am KemPharm presents data on KP511 and KP201/IR at the American Academy of Pain Medicine Annual Meeting - March 16 at 6:58 PM logoKEMPHARM, INC Financials - March 16 at 6:58 PM logoCan The Uptrend Continue for KemPharm (KMPH)? - March 15 at 6:27 PM logoKemPharm Inc (KMPH) Upgraded by Zacks Investment Research to “Buy” - March 15 at 12:24 AM logoOppenheimer Holdings Comments on KemPharm Inc’s FY2021 Earnings (KMPH) - March 13 at 2:48 PM logoKEMPHARM, INC Files SEC form 10-K, Annual Report - March 10 at 7:23 PM logoKemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results - GlobeNewswire (press release) - March 10 at 7:57 AM logoKemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results - March 9 at 9:06 PM logoQ4 2016 KemPharm Inc Earnings Release - After Market Close - March 9 at 8:48 AM logoKemPharm Inc (KMPH) Set to Announce Earnings on Thursday - March 8 at 9:19 AM logoKemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results - February 28 at 9:37 AM logo7:31 am KemPharm announces issuance of two new patents by the USPTO, one related to the KP511 family of compounds and another related to KP201 - February 23 at 6:09 PM logoKEMPHARM, INC Files SEC form 8-K, Change in Directors or Principal Officers - February 16 at 5:50 PM logoKemPharm to Present at Upcoming Investor Conferences - February 7 at 7:27 PM logoSHAREHOLDER ALERT: Goldberg Law PC Announces an ... - Business Wire (press release) - February 4 at 4:53 AM logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of KemPharm, Inc. and Advises Investors with Losses to Contact the Firm - February 3 at 11:52 PM



KemPharm (KMPH) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by Staff